Presbia PLC

Presbia — Jefferies Healthcare Conference 2017

17 slides from Presbia's conference presentation, May 31, 2017

  1. Slide 1: Jefferies Healthcare Conference

    Slide 1: Jefferies Healthcare Conference

    Jefferies Healthcare Conference **Confidential** June 2017 CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use. Exhibit 99.1

  2. Slide 2: Disclosure

    Slide 2: Disclosure

    Disclosure To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward

  3. Slide 3: Business Highlights

    Slide 3: Business Highlights

    Business Highlights 118 million presbyopes in the U.S.; 1.9 billion presbyopes worldwide (2016)* Large, Underserved Presbyopia Opportunity Best-in-Class Microlens Technology Strong Leadership and Compelling Business Model Refractive corneal inlay restores reading vision—on average 5 lines of improve

  4. Slide 4: Presbia Restores Near Vision

    Slide 4: Presbia Restores Near Vision

    Presbia Restores Near Vision Presbia has developed a solution for presbyopia, an age related condition affecting people from approximately 40 years of age, to help restore near vision Safe, effective and minimally invasive surgical procedure Currently marketed in certain markets outside the United S

  5. Slide 5: The Presbia Procedure: True Microlens

    Slide 5: The Presbia Procedure: True Microlens

    True “Microlens” with 3.2 mm diameter and edge thickness of 0.015 mm Hydrophilic acrylic material similar to that used in IOLs for > 20 years Invisible to the naked eye once implanted Can be done concurrently or pre/post LASIK or cataract surgery Offered in a wide range of powers ranging from +1.5 d

  6. Slide 6: The Presbia Flexivue Microlens

    Slide 6: The Presbia Flexivue Microlens

    The Presbia Flexivue MicrolensTM The Presbia Flexivue Microlens™ is a best in class treatment option for presbyopia A powered corneal inlay is implanted in the non-dominant eye, with minimal impact to binocular distance vision Presbia has unique competitive advantages A refractive lens like reading

  7. Slide 7: Competitive Landscape

    Slide 7: Competitive Landscape

    Competitive Landscape AcuFocus - KAMRA Non-powered “disc” implanted in the non-dominant eye Utilizes the “pinhole effect” to focus light to enhance near vision The disc is visible to naked eye in light colored eyes Difficult for patient in low light environments Obstructs the view of the retina in d

  8. Slide 8: Large, Underserved and Growing Commercial/Market Opportunity

    Slide 8: Large, Underserved and Growing Commercial/Market Opportunity

    Large, Underserved and Growing Commercial/Market Opportunity 1.9 Billion Presbyopes Source: 2016 Market Scope Refractive Surgery Report (millions)

  9. Slide 9: The Physician Appeal

    Slide 9: The Physician Appeal

    The Physician Appeal LASIK Cataract Presbyopia No established surgical market for the 40–60 year old patient pool 20s 30s 40s 50s 60s 70s 80s ? ? ? Presbia provides ophthalmologist with an exciting new option to treat patients with presbyopia Incremental revenue driver No capital expenditure require

  10. Slide 10: Commercial Opportunity - LASIK as a Market Benchmark

    Slide 10: Commercial Opportunity - LASIK as a Market Benchmark

    Commercial Opportunity - LASIK as a Market Benchmark * Market Scope, 2014 Corneal inlay has the potential to impact the Presbyopia market similar to LASIK’s impact on vision correction in younger patients Presbia Flexivue Microlens™ requires a less invasive procedure About 1.6x more people suffer fr

  11. Slide 11: Focused Commercial Strategy

    Slide 11: Focused Commercial Strategy

    Focused Commercial Strategy Build global KOL acceptance carrying momentum into US commercial launch Registered to commercialize in 42 different countries Clinics implanting in South Korea, Germany, Ireland, UK, Netherlands, Australia/NZ, and Canada Gain FDA approval and begin marketing in the United

  12. Slide 12: Compelling Results

    Slide 12: Compelling Results

    Compelling Results Subjects can perform almost all near vision tasks without glasses For example, an improvement from reading a subhead in the newspaper (12pt font) to reading the content label (4pt font) on a medicine bottle

  13. Slide 13: Improvement in Uncorrected Near Visual Acuity in Operated Eyes

    Slide 13: Improvement in Uncorrected Near Visual Acuity in Operated Eyes

    Improvement in Uncorrected Near Visual Acuity in Operated Eyes ~20/80 ~20/25 +5 line improvement in Uncorrected Near Visual Acuity in treated eyes compared to preoperative visual acuity

  14. Slide 14: No change in Binocular Uncorrected Distance Visual Acuity

    Slide 14: No change in Binocular Uncorrected Distance Visual Acuity

    No change in Binocular Uncorrected Distance Visual Acuity 20/16 to 20/25 ≥ 96% of Subjects with Uncorrected Distance Visual Acuity Preoperatively and at Month 18 between 20/16 and 20/25

  15. Slide 15: US Registration Timeline

    Slide 15: US Registration Timeline

    Sept 2015: Completion of 2nd Stage Enrollment (a total of 346 subjects) Throughout 2016 into 2017: Focus is on Compliance – constant subject follow through Q4 2017: Submit Clinical Data in Final PMA Module to FDA (300 subjects, 2 year data) Q3 2018: Anticipate Approval 421st Subject Treated 9/11/15

  16. Slide 16: Business Highlights

    Slide 16: Business Highlights

    Business Highlights 118 million presbyopes in the U.S.; 1.9 billion presbyopes worldwide (2016)* Large, Underserved Presbyopia Opportunity Best-in-Class Microlens Technology Strong Leadership and Compelling Business Model Refractive corneal inlay restores reading vision—on average 5 lines of improve

  17. Slide 17: CAUTION - Investigational Device

    Slide 17: CAUTION - Investigational Device

    CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.

Source: SEC EDGAR · 8-K filed May 31, 2017

More decks from Presbia PLC